Navigation Links
Genoptix Reports Strong Growth for the First Quarter of 2009

Company Reports Record Revenues of $39.2 Million

CARLSBAD, Calif., April 30 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today reported revenues of $39.2 million for the first quarter of 2009, which includes a $2.0 million benefit from changes in accounting estimates relating to prior periods. This is an increase of approximately 76% over revenues of $22.3 million for the comparable period in 2008, which included a $651 thousand benefit from changes in accounting estimates.

"We started 2009 with another quarter of solid performance, reaching a record 1,200 actively ordering physician customers as the appeal of our high quality service offerings continue to drive our growth and expansion of our market share," said Tina S. Nova, Ph.D., President and CEO of Genoptix. "We managed nearly 13,000 patient cases in the first quarter of 2009, an increase of 65% from the first quarter of 2008. As we grow, it is our goal to facilitate personalized medicine by providing clinically relevant and actionable results with exceptional service, a strategy that is at the foundation of our success."

Gross profit for the first quarter of 2009 was $23.8 million, up from $13.1 million for the first quarter of 2008, or 60.6% of revenues as compared to 58.9% of revenues, respectively.

Operating expenses for the first quarter of 2009 increased to $13.6 million from $9.0 million for the first quarter of 2008, an increase driven by investment in infrastructure and personnel to support rapid organizational growth. Operating income for the first quarter of 2009 was $10.1 million, or 25.9% of revenues, as compared to operating income of $4.2 million, or 18.6% of revenues, for the same period in 2008.

Our tax rate was 44.2% for the first quarter, increasing from 2.1% for the first quarter of 2008. In the first quarter of 2009, the Company operated as a fully taxed corporation, following the recognition of the remaining available deferred tax assets in the last half of 2008.

Net income was $5.9 million for the first quarter of 2009, compared to net income of $5.0 million for the first quarter of 2008. Diluted earnings per share, or EPS, for the first quarter of 2009 was $0.33 based on 17.8 million weighted average common shares outstanding. This compares to EPS of $0.29 for the first quarter of 2008, which would have been reduced by approximately $0.13 if taxed at the current rate.

As of March 31, 2009, the Company's total cash, cash equivalents and investment securities were $111.5 million. For the first quarter of 2009, cash generated from operations was $5.3 million, while purchases of capital equipment for the same period totaled $1.6 million. The first quarter of 2009 ended with bad debt expense at approximately 3% of total revenues and days sales outstanding of 67 days, down from 71 days in the first quarter of 2008.

"We have continued to develop and strengthen the organization in the first quarter, moving forward with our growth initiatives and our hiring plan. In the first quarter, our sales team grew to 62 field representatives, up from 55 at the end of 2008 and moving us closer to our goal of 85 representatives by the end of 2009," said Sam Riccitelli, Genoptix EVP and COO. "We also increased the size of the Cartesian Medical Group, bringing the total number of hematopathologists to 26 and keeping us on track toward our goal of housing approximately 37 physicians by year-end."

Revised 2009 Performance Outlook

For the full-year 2009, Genoptix expects revenues of between $170 to $175 million, up from previous expectations of approximately $170 million, with gross margins in the high-fiftieth percentile.

Operating margins for 2009 are expected to be in the low-twentieth percentile, while net income is expected to be approximately $22 million, up from prior estimates of $21 million. Diluted EPS for the full-year 2009 is increasing from approximately $1.15 and is now expected to be between $1.20 to $1.25 on approximately 18.1 million shares assuming a tax rate of 45% in the Company's first year operating as a fully-taxed entity.

Based on continued infrastructure expansion and implementation of its strategic plan, the Company projects capital expenditures of approximately $8 million for the full-year 2009, which includes approximately $4.5 million in maintenance capital.

Conference Call Information

A conference call will take place on Thursday, April 30, 2009, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO, Tina S. Nova, Ph.D., and other members of senior management. To access the live conference call via phone, dial 866-383-8119 in the U.S. or Canada and 617-597-5344 for international callers. Please specify to the operator that you would like to join the "Genoptix First Quarter 2009 Earnings Conference Call." The participant code for the call is 67492694. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, May 7, 2009. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 17952469.

The conference call will also be webcast live on the investor relations section of the Genoptix website at Please connect to the Genoptix website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. If you are unable to listen to the live webcast, a replay will be available through Thursday, May 28, 2009, on the Genoptix website at

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the Company's business that are not historical facts may be considered "forward-looking statements," including statements regarding the value of the Company's services, the Company's ability to provide high quality services and facilitate personalized medicine, the success of the Company's business model, improving case volumes, increasing revenues, customer adoption and growth, the Company's capacity to manage and support future growth and ability to expand its business, hire additional personnel and consistently provide specialized, personalized and comprehensive diagnostic services, the Company's growth prospects and ability to capture additional bone marrow market share in the U.S., estimated effective tax rates and the Company's financial guidance for 2009. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted include, without limitation, commercial and governmental reimbursement decisions, compliance and regulatory risks, financial risks, the Company's ability to hire personnel and manage its growth and the competitive landscape within our industry. These and other risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and most recent Quarterly Report on Form 10-Q and subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

                            (Financial tables follow)

                                  GENOPTIX, INC.
                      (in thousands, except per share data)

                                                   Three Months Ended
                                                        March 31,
                                                   2009           2008
    Revenues                                     $39,189        $22,298
    Cost of revenues                              15,429          9,175
    Gross profit                                  23,760         13,123
    Operating expenses:
      Sales and marketing                          6,990          4,261
      General and administrative                   6,390          4,388
      Research and development                       240            317
    Total operating expenses                      13,620          8,966
    Income from operations                        10,140          4,157
    Interest and other income                        501            959
    Income before income taxes                    10,641          5,116
    Income tax expense                             4,699            109
    Net income                                    $5,942         $5,007
    Net income per share:
      Basic                                        $0.35          $0.31
      Diluted                                      $0.33          $0.29
    Shares used to compute net income per share:
      Basic                                       16,747         16,156
      Diluted                                     17,836         17,493

                                  GENOPTIX, INC.
                                  (in thousands)

                                                  March 31,    December 31,
                                                     2009          2008
    Current assets:
      Cash and cash equivalents                     $23,683       $38,108
      Short-term investment securities               83,691        64,830
      Accounts receivable, net of allowance for
       doubtful accounts                             24,581        15,604
      Deferred tax asset                              4,735         4,707
      Other current assets                            1,999         2,179
    Total current assets                            138,689       125,428
    Property and equipment, net                      12,514        12,189
    Long-term investment security                     3,775         3,775
    Long-term deferred tax asset                      2,500         2,510
    Restricted cash                                     360           360
    Other long-term assets                              322           183
    Total assets                                   $158,160      $144,445

    Liabilities and Stockholders' Equity
    Current liabilities:
      Accounts payable and accrued expenses          $7,014        $6,580
      Accrued compensation                            4,057         3,006
      Income tax payable                              2,491             -
      Deferred revenues                                 844           365
      Deferred rent                                     261           241
    Total current liabilities                        14,667        10,192
    Long-term deferred rent                           1,879         1,955
    Other long-term liabilities                         300            79
    Stockholders' equity:
      Preferred stock                                     -             -
      Common stock                                       17            17
    Additional paid-in capital                      146,754       143,616
    Accumulated other comprehensive loss               (759)         (774)
    Accumulated deficit                              (4,698)      (10,640)
    Total stockholders' equity                      141,314       132,219
    Total liabilities and stockholders' equity     $158,160      $144,445

                                  GENOPTIX, INC.
                                  (in thousands)

                                                         Three Months Ended
                                                              March 31,
                                                         2009           2008
    Operating activities:
      Net income                                        $5,942         $5,007
      Adjustments to reconcile net income to net cash
       provided by operating activities:
        Depreciation and amortization                      793            198
        Provision for doubtful accounts                  1,022            624
        Stock-based compensation expense                 2,311            881
        Excess tax benefits from stock-based
         compensation awards                            (1,022)           (60)
        Amortization of premium/discount on investment
         securities                                        (81)           (19)
        Deferred taxes                                     (28)             -
        Loss (gain) on sale of property and equipment        6            (19)
      Changes in operating assets and liabilities:
        Accounts receivable                             (9,999)        (6,824)
        Other current and long-term assets                  87            139
        Accounts payable and accrued expenses              948            991
        Accrued compensation                             1,051           (184)
        Income taxes                                     3,771           (158)
        Deferred revenues                                  479            (27)
        Deferred rent                                        1             32
    Net cash provided by operating activities            5,281            581
    Investing activities:
      Purchase of property and equipment                (1,628)        (1,345)
      Proceeds from sales of property and equipment          -             20
      Purchase of investment securities                (48,099)       (47,705)
      Proceeds from sales and maturities of investment
      securities                                        29,344         29,850
      Purchase of intangibles                             (150)             -
    Net cash used in investing activities              (20,533)       (19,180)
    Financing activities:
      Proceeds from issuance of common stock, net          133            134
      Excess tax benefits from stock-based
       compensation awards                               1,022             60
      Repurchase of restricted stock for payment of
       taxes                                              (328)             -
      Costs paid in connection with public offerings         -           (286)
    Net cash provided by (used in) financing
     activities                                            827            (92)
    Net decrease in cash and cash equivalents          (14,425)       (18,691)
    Cash and cash equivalents at beginning of period    38,108         50,624
    Cash and cash equivalents at end of period         $23,683        $31,933
    Supplemental information:
    Income taxes paid                                     $958           $236
    Non-cash investing and financing activities:
    Unrealized gain on investment securities, net          $25            $18
    Change in accrued purchases of property and
     equipment                                           $(452)            $-

SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. Genoptix Announces Pricing of Secondary Public Offering
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
9. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
10. Genoptix Reports Strong Financial Results for First Quarter 2008
11. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Post Your Comments:
(Date:10/10/2015)... , ... October 10, 2015 , ... The sixth annual ... on the growth of cybercrime costs for US companies. The New York Times broke ... 6th. With averages showing increases hovering around 20% among the companies surveyed, it only ...
(Date:10/10/2015)... Arbor, MI (PRWEB) , ... October 10, 2015 , ... ... City, MO. , On the heels of the release of the Institute of ... of tools, and their integration with Cerner solutions that assist healthcare providers and consumers ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
(Date:10/9/2015)... ... October 09, 2015 , ... A new health tool ... Aid, is now available online ( ) – just in time for the ... officially begins in October. However, for many in the U.S., the real start of ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... a special promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. ... are almost invisible against the teeth, which allow patients to complete treatment in ...
Breaking Medicine News(10 mins):
... (HealthDay News) -- Drinking too much alcohol can lead to ... the most common cause of HIV infection and finding ways ... health efforts to prevent HIV/AIDS. Alcohol use has long ... whether unsafe sex associated with alcohol use actually led to ...
... MONDAY, Dec. 12 (HealthDay News) -- Breast cancer survivors ... treatment with radiation and/or chemotherapy, a new study says. ... and treatment-specific ways that these cancer therapies impair cancer ... Moffitt Cancer Center and Research Institute in Tampa, Fla., ...
... , Researchers at the Norwegian University of Life Sciences ... new method for detailed analyses of electrical activity in ... can help doctors and researchers to better interpret ... considerable steps forward in terms of interpreting for example ...
... has found that alcohol consumption directly impacts a person,s intention to ... the stronger becomes your intention to engage in unsafe sex. ... infection, and it is a main risk factor for the global ... prevent unsafe sex, HIV incidence in most high income countries (such ...
... leukemia patients, own infection-fighting cells appears to protect ... with fludarabine-based chemotherapy, according to new research from ... of Pennsylvania. The new process is a step ... from the commonly prescribed drug, which improves progression-free ...
... Researchers at the Stanford University School of Medicine report ... physical force contributes to scarring in mice. "Our ... the mechanical environment can directly increase inflammation, which is ... and associate chair of surgery. Mice genetically engineered ...
Cached Medicine News:
(Date:10/8/2015)... Oct. 8, 2015  Trovagene, Inc., (NASDAQ:   ... announced the presentation of results from a field ... Cancer Monitoring SM (PCM) platform to accurately ... physicians to determine appropriate therapy for patients. ... Trovagene is delivering the results today in an ...
(Date:10/8/2015)... New York , October 8, 2015 ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - ... was valued at USD 2.63 billion in 2013 and is ... to 2022 to reach USD 4.00 billion in 2022. ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ...
(Date:10/8/2015)... DUBLIN , Oct. 08 2015 /PRNewswire/ ... announced the addition of the "Natural ... Life Sciences Industry by Type (Rule-Based, Statistical, ... Europe, Asia-Pacific, Middle East and Africa, Latin ... report to their offering. --> ...
Breaking Medicine Technology:
... 2011 Actavis Group, the international generic pharmaceuticals company, today ... a binding letter of intent (LOI) with QRxPharma Limited (ASX: ... United States.  Under the terms of the ... IR, a patented 3:2 ratio fixed dose combination of morphine ...
...  QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution ... for the formation of a strategic partnership to commercialise MoxDuo ... IR is a patented 3:2 ratio fixed dose combination of ... Group, hf a privately held company based in Europe with ...
Cached Medicine Technology:
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... Distriman is a ... that is designed to ... used with Gilson DistriTip ... polypropylene syringes with level ...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... Plus, a handheld manual dispenser, is ideal ... long series pipetting. Its increased volume selection ... research tasks, and its smooth handling reduces ... The nine Combitips allow a wider range ...
Medicine Products: